Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients
- 13 July 2021
- journal article
- letter
- Published by Elsevier BV in Kidney International
- Vol. 100 (3), 698-700
- https://doi.org/10.1016/j.kint.2021.07.006
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’Annals Of The Rheumatic Diseases, 2021
- SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipientsScience Immunology, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Elucidating reasons of COVID-19 re-infection and its management strategiesDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021
- SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis populationKidney International, 2021
- mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognitionPublished by Cold Spring Harbor Laboratory ,2021
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraCell, 2021
- Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variantPublished by Cold Spring Harbor Laboratory ,2021
- Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTANephrology Dialysis Transplantation, 2020
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020